Charles River Labs (CRL) Receives a Hold from Barclays


Barclays analyst Jack Meehan maintained a Hold rating on Charles River Labs (CRL) yesterday and set a price target of $135. The company’s shares closed yesterday at $139.12, close to its 52-week high of $139.91.

According to TipRanks.com, Meehan is a 4-star analyst with an average return of 5.7% and a 62.5% success rate. Meehan covers the Healthcare sector, focusing on stocks such as Bio-Rad Laboratories, Syneos Health Inc, and Myriad Genetics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Charles River Labs with a $141.63 average price target, a 1.8% upside from current levels. In a report released yesterday, Credit Suisse also maintained a Hold rating on the stock with a $110 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $139.91 and a one-year low of $101.58. Currently, Charles River Labs has an average volume of 384.8K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Charles River Laboratories International, Inc. is an early-stage contract research company, which provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts